Avidity Biosciences (RNA) said Monday it completed enrollment in the biomarker group in a phase 1/2 trial of delpacibart braxlosiran, or del-brax, in people with facioscapulohumeral muscular dystrophy, a genetic muscle disorder.
The company said 51 participants were enrolled in the biomarker group.
The del-brax biomarker group was designed for a potential accelerated approval in the US, Avidity said, adding it plans to release a regulatory update in Q2.
The company's shares were down 6% in recent trading.
Price: 29.69, Change: -1.91, Percent Change: -6.04
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.